David Robert Spigel
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.02%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 209
- Cancer Immunotherapy and Biomarkers 82
- Lung Cancer Research Studies 71
- Colorectal Cancer Treatments and Studies 27
- Cancer Diagnosis and Treatment 14
-
- Lung Cancer Treatments and Mutations 102
- Lung Cancer Diagnosis and Treatment 29
- Co-authors
- John Daniel Hainsworth (78 shared papers)F. Anthony Greco (66 shared papers)Howard A. Burris (71 shared papers)Scott Joseph Antonia (16 shared papers)David Michael Waterhouse (24 shared papers)Mark A. Socinski (18 shared papers)Harvey J. Murff (2 shared papers)Lecia Van Dam Sequist (9 shared papers)
- Journals
- Annals of Oncology (70 papers)Journal of Thoracic Oncology (50 papers)Journal of Clinical Oncology (48 papers)Clinical Lung Cancer (16 papers)Cancer (13 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
David Robert Spigel
358 papers receiving 59.4k citations
David Robert Spigel's Hit Papers
Peers
Comparison fields: 5 of 156
- Oncology 39.5k
- Pulmonary and Respiratory Medicine 18.8k
- Immunology 10.5k
- Cancer Research 5.8k
- Pathology and Forensic Medicine 3.1k
Countries citing papers authored by David Robert Spigel
This map shows the geographic impact of David Robert Spigel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Robert Spigel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Robert Spigel more than expected).
Fields of papers citing papers by David Robert Spigel
This network shows the impact of papers produced by David Robert Spigel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Robert Spigel. The network helps show where David Robert Spigel may publish in the future.
Co-authors
The 25 scholars most cited alongside David Robert Spigel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 364 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Hit paper breakdown → | 2012 | 10591 |
| 2 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 8004 |
| 3 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 7150 |
| 4 | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC Hit paper breakdown → | 2018 | 2228 |
| 5 | Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2019 | 1711 |
| 6 | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma Hit paper breakdown → | 2018 | 1296 |
| 7 | Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC Hit paper breakdown → | 2020 | 1271 |
| 8 | Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA Hit paper breakdown → | 2020 | 1052 |
| 9 | Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 1010 |
| 10 | Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) Hit paper breakdown → | 2017 | 736 |
| 11 | First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations Hit paper breakdown → | 2008 | 726 |
| 12 | A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 722 |
| 13 | Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study Hit paper breakdown → | 2018 | 610 |
| 14 | Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2020 | 516 |
| 15 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Hit paper breakdown → | 2018 | 496 |
| 16 | Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab Hit paper breakdown → | 2019 | 484 |
| 17 | First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers Hit paper breakdown → | 2019 | 483 |
| 18 | Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2021 | 477 |
| 19 | Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2017 | 471 |
| 20 | Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study Hit paper breakdown → | 2016 | 468 |
About David Robert Spigel
David Robert Spigel is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Epidemiology, having authored 364 papers that have together received 60.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (102 papers), Cancer Immunotherapy and Biomarkers (82 papers), Lung Cancer Research Studies (71 papers), Lung Cancer Diagnosis and Treatment (29 papers), Colorectal Cancer Treatments and Studies (27 papers), Cancer Genomics and Diagnostics (16 papers), Neuroendocrine Tumor Research Advances (16 papers) and Cancer Diagnosis and Treatment (14 papers). The work is most often cited by research in Oncology (39.5k citations), Pulmonary and Respiratory Medicine (18.8k citations), Immunology (10.5k citations), Cancer Research (5.8k citations) and Pathology and Forensic Medicine (3.1k citations). David Robert Spigel has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include John Daniel Hainsworth, F. Anthony Greco, Howard A. Burris, Scott Joseph Antonia, David Michael Waterhouse, Mark A. Socinski, Harvey J. Murff, Lecia Van Dam Sequist, Charles Swanton and David A. McCollum. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Journal of Clinical Oncology, Clinical Lung Cancer and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.